Post by Stockhead

Health Check by Tim Boreham: Commercial rollouts and strategic stakes are in focus as #ASX #biotech players look to build on the June momentum. Imricor shares surged 16% after securing FDA clearance for its MRI-guided diagnostic heart catheter and Northstar guidance system. BCAL Diagnostics acquired a 10.2% stake in molecular diagnostics peer Genetic Signatures, looking to build out a broader, multi-pillar testing platform. Read the full article: https://buff.ly/B1lEUXL #Investing #MedTech #Health